Kindred Biosciences, Inc. (NASDAQ:KIN) price closed higher on Friday, Jan 22, jumping 10.79% above its previous close.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

A look at the daily price movement shows that the last close reads $4.45, with intraday deals fluctuated between $4.3304 and $4.9700. The company’s 5Y monthly beta was ticking 1.21 while its P/E ratio in the trailing 12-month period read 0. Taking into account the 52-week price action we note that the stock hit a 52-week high of $11.93 and 52-week low of $3.11. The stock added 20.54% on its value in the past month.

Kindred Biosciences, Inc., which has a market valuation of $175.51 Million, is expected to release its quarterly earnings report in Mar 2021. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Analysts tracking KIN have forecast the quarterly EPS to grow by -$0.29 per share this quarter, while the same analysts predict the annual EPS to hit -$0.58 for the year 2021 and up to -$0.77 for 2022. In this case, analysts estimate an annual EPS growth of -0.64% for the year and 0.33% for the next year.

On average, analysts have forecast the company’s revenue for the quarter will hit $1.05 Million, with the likely lows of $700Million and highs of $1.3 Million. The average estimate suggests sales growth for the quarter will likely fall by -25.1% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $42.15 Million for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to grow +890.4% above that which the company brought in 2020.

On the technical perspective front, indicators give KIN a short term outlook of 100% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a Hold, while an average of long term indicators are currently assigning the stock as 75% Buy.

Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 7 analysts have assigned KIN a recommendation rating as follows: 1 rate it as a Hold; 6 advise Buy while none analyst(s) assign an Outperform rating. None analyst(s) have tagged the Kindred Biosciences, Inc. (KIN) stock as Underperform, with none recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.

If we dive deeper into the stock’s performance we see the positive picture represented by the PEG ratio, currently standing at 0. The overview shows that KIN’s price is at present 5.55% off the SMA20 and 17.58% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 58.32, with weekly volatility standing at 9.19%. The indicator drops to 7.42% when calculated based on the past 30 days. Kindred Biosciences, Inc. (NASDAQ:KIN)’s beta value is holding at 1.21, while the average true range (ATR) indicator is currently reading 0.33. Considering analysts have assigned the stock a price target range of $9-$12 as the low and high respectively, we find the trailing 12-month average consensus price target to be $10.38. Based on this estimate, we see that current price is roughly 82.56% off the estimated low and 143.41% off the forecast high. Investors will no doubt be excited to see the share price rise to $10.5, which is the median consensus price, and at that level KIN would be +112.98% from current price.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Turning out attention to how the Kindred Biosciences, Inc. stock has performed in comparison to its peers in the industry, here’s what we find: KIN’s stock is +10.79% on the day and -48.96% in the past 12 months, while Amgen Inc (AMGN) traded +0.58% in the last session and was positioned +7.85% up on its price 12 months ago. Another comparison is with Bristol-Myers Squibb Company (BMY) whose stock price was up 0.59% in the last trading session, but has tanked -3.45% over the past year. Also, Gilead Sciences Inc (GILD) showed uptrend of 10.79% while its price kept floating at -48.96% over the past year. As for Kindred Biosciences, Inc., the P/E ratio stands at 0 lower than that of Amgen Inc’s at 20.44 and Bristol-Myers Squibb Company’s 0. Elsewhere in the market, the S&P 500 Index has fell -0.3% in last trading session, with the Dow Jones Industrial also saw a negative session on the day with -0.57%.

An analysis of the Kindred Biosciences, Inc. (NASDAQ:KIN) stock in terms of its daily trading volume indicates that the 3-month average is 243.84 Million. However, this figure increases on the past 10-day timeline to an average of 448.02 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Curent records show that the company has 39.49 Million in outstanding shares. According to data from Thomson Reuters, insiders’ percentage holdings are 6.16% of outstanding shares while the percentage share held by institutions stands at 67.9%. The stats also highlight that short interest as of December 30, 2020, stood at 760.02 Million shares, which puts the short ratio at the time at 3.17. From this we can glean that short interest is 1.93% of company’s current outstanding shares. Notably, we see that shares short in December rose slightly given the previous month’s figure stood at 691.98 Million. But the +14.39% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on.

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

LEAVE A REPLY

Please enter your comment!
Please enter your name here